The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial
Open Access
- 6 March 2024
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (9) , 2122-2132
Abstract
Background: Although both pharmacotherapy and psychological treatments are considered to be efficacious in the treatment of major depressive disorder (MDD), one third of patients do not respond to treatment and many experience residual symptoms post-treatment. In this double-blind placebo-controlled randomized control trial (RCT), we assessed whether intranasal oxytocin (OT) augments the therapeutic efficacy of psychotherapy for MDD and improves the therapeutic alliance.Methods: Twenty-three volunteers (12 female) with MDD underwent 16 sessions of interpersonal therapy. Prior to each session, volunteers self-administered 24 International Units of intranasal OT (n = 12; Syntocinon) or placebo (n = 11). Depressive symptoms were assessed with the Inventory of Depressive Symptomatology at pre- and post-treatment, and at a six month follow-up.Results: Multilevel modeling found a significant effect of OT on the negative slope of depressive symptoms over time (p < 0.05), with medium-large effect sizes at post-treatment (Cohen's d = 0.75) and follow-up (Cohen's d = 0.82). Drug intervention also predicted the intercept when examining the weekly ratings of the therapeutic alliance (p < 0.05), such that volunteers receiving OT, relative to placebo, reported improved therapeutic alliance at session 1. The agreement of goals between therapists and participants, a facet of the therapeutic alliance, mediated the relationship between drug intervention and clinical outcome.Conclusion: In this pilot study, the administration of intranasal OT, relative to placebo, improved the therapeutic alliance at the beginning of therapy and therapeutic efficacy of psychotherapy in persons with MDD. Future RCTs should attempt to replicate these findings in larger samples with different therapeutic modalities (ClinicalTrials.gov: NCT02405715).Keywords
This publication has 67 references indexed in Scilit:
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- The Relation between Improvement in the Therapeutic Alliance and Interpersonal Functioning for Individuals with Emotional DisordersInternational Journal of Cognitive Therapy, 2019
- ACUTE AND CHRONIC STRESS EXPOSURE PREDICTS 1-YEAR RECURRENCE IN ADULT OUTPATIENTS WITH RESIDUAL DEPRESSION SYMPTOMS FOLLOWING RESPONSE TO TREATMENTDepression and Anxiety, 2013
- Inter‐rater reliability of the Structured Clinical Interview for DSM‐IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II)Clinical Psychology & Psychotherapy, 2011
- A review of empirically supported psychological therapies for mood disorders in adultsDepression and Anxiety, 2010
- Intranasal Oxytocin Increases Positive Communication and Reduces Cortisol Levels During Couple ConflictBiological Psychiatry, 2009
- Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe DepressionArchives of General Psychiatry, 2005
- Cognitive Therapy vs Medications in the Treatment of Moderate to Severe DepressionArchives of General Psychiatry, 2005
- One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studiesBiological Psychiatry, 2004
- The inventory for depressive symptomatology (IDS): Preliminary findingsPsychiatry Research, 1986